Several trials with extended follow-up periods, such as the Stockholm3 and ProtecT trials, have also demonstrated the benefits of taking repeated PSA dosages between 3 and 10 ng/mL when there is a clinically uncertain suspicion of PCa to avoid these unnecessary biopsies, which is now part of current guidelines [10]. The gene discussed is KLK3; the disease is posterior cortical atrophy.